Reductions in eosinophil biomarkers by benralizumab in patients with asthma
Eosinophilic inflammation is frequently associated with increased asthma severity. Benralizumab is a humanized, afucosylated, anti–interleukin-5Rα monoclonal antibody that selectively depletes eosinophils and basophils through enhanced antibody-dependent cell-mediated cytotoxicity.
Source: Respiratory Medicine CME - Category: Respiratory Medicine Authors: Tuyet-Hang Pham, Gautam Damera, Paul Newbold, Koustubh Ranade Source Type: research
More News: Asthma | Respiratory Medicine